China Pharma Holdings, Inc. (CPHI): Price and Financial Metrics


China Pharma Holdings, Inc. (CPHI): $0.61

-0.02 (-2.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CPHI to Watchlist
Sign Up

Industry: China


Ranked

of 65

in industry

CPHI POWR Grades


  • CPHI scores best on the Sentiment dimension, with a Sentiment rank ahead of 78.44% of US stocks.
  • The strongest trend for CPHI is in Momentum, which has been heading down over the past 35 weeks.
  • CPHI ranks lowest in Momentum; there it ranks in the 15th percentile.

CPHI Stock Summary

  • With a market capitalization of $27,455,121, China Pharma Holdings Inc has a greater market value than only 2.38% of US stocks.
  • Price to trailing twelve month operating cash flow for CPHI is currently 53.88, higher than 91.51% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 26.73%, China Pharma Holdings Inc's debt growth rate surpasses 80.87% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to China Pharma Holdings Inc are MFGP, PFIE, MGIC, JOUT, and IOSP.
  • CPHI's SEC filings can be seen here. And to visit China Pharma Holdings Inc's official web site, go to www.chinapharmaholdings.com.

CPHI Valuation Summary

  • CPHI's EV/EBIT ratio is -10.3; this is 135.15% lower than that of the median Healthcare stock.
  • CPHI's price/earnings ratio has moved down 10.5 over the prior 154 months.
  • Over the past 154 months, CPHI's price/earnings ratio has gone down 10.5.

Below are key valuation metrics over time for CPHI.

Stock Date P/S P/B P/E EV/EBIT
CPHI 2021-08-31 3.0 4.6 -7.8 -10.3
CPHI 2021-08-30 2.9 4.6 -7.8 -10.3
CPHI 2021-08-27 3.0 4.7 -8.1 -10.6
CPHI 2021-08-26 3.1 4.9 -8.3 -10.9
CPHI 2021-08-25 3.1 4.9 -8.3 -10.9
CPHI 2021-08-24 3.1 4.8 -8.3 -10.8

CPHI Growth Metrics

  • Its year over year price growth rate is now at 20.45%.
  • The 2 year revenue growth rate now stands at -27.94%.
  • The 4 year cash and equivalents growth rate now stands at -93.43%.
Over the past 55 months, CPHI's revenue has gone down $5,464,813.

The table below shows CPHI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 10.1057 0.5096 -3.811021
2021-03-31 11.46087 -0.075021 -2.973207
2020-12-31 10.86645 -0.04226 -2.866777
2020-09-30 10.98376 -1.172494 -20.403
2020-06-30 10.95993 -0.476228 -20.09405
2020-03-31 9.758618 0.273634 -20.94521

CPHI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CPHI has a Quality Grade of C, ranking ahead of 56.06% of graded US stocks.
  • CPHI's asset turnover comes in at 0.493 -- ranking 88th of 677 Pharmaceutical Products stocks.
  • DRNA, ONVO, and CASI are the stocks whose asset turnover ratios are most correlated with CPHI.

The table below shows CPHI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.493 0.094 -0.236
2021-03-31 0.538 0.177 -0.174
2020-12-31 0.495 0.180 -0.168
2020-09-30 0.494 0.153 -1.332
2020-06-30 0.407 0.183 -0.990
2020-03-31 0.306 0.105 -0.802

CPHI Stock Price Chart Interactive Chart >

Price chart for CPHI

CPHI Price/Volume Stats

Current price $0.61 52-week high $1.63
Prev. close $0.63 52-week low $0.35
Day low $0.61 Volume 98,700
Day high $0.63 Avg. volume 1,771,969
50-day MA $0.74 Dividend yield N/A
200-day MA $0.74 Market Cap 26.76M

CPHI Latest News Stream


Event/Time News Detail
Loading, please wait...

CPHI Latest Social Stream


Loading social stream, please wait...

View Full CPHI Social Stream

Latest CPHI News From Around the Web

Below are the latest news stories about China Pharma Holdings Inc that investors may wish to consider to help them evaluate CPHI as an investment opportunity.

7 Discord Stocks Investors Are Pumping Higher

Move over Reddit!

Josh Enomoto on InvestorPlace | August 23, 2021

China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021.

Yahoo | August 13, 2021

China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's (NMPA) approval. The NMPA is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administr

Yahoo | August 5, 2021

China Pharma to Launch Highly Purified NMN+PQQ Product

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test. β-Nicotinamide mononucleotide (NMN) is a derivative of the B-vitamin niacin, which is believed to significantly improve health and wellness.

Yahoo | June 9, 2021

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 2020.

Yahoo | March 26, 2021

Read More 'CPHI' Stories Here

CPHI Price Returns

1-mo -13.30%
3-mo -12.10%
6-mo -34.65%
1-year 66.44%
3-year 177.27%
5-year 165.22%
YTD 36.83%
2020 88.26%
2019 -7.86%
2018 42.78%
2017 -30.77%
2016 62.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8152 seconds.